INTRAVITREOUS AND PLASMA-CONCENTRATIONS OF GANCICLOVIR AND FOSCARNET AFTER INTRAVENOUS THERAPY IN PATIENTS WITH AIDS AND CYTOMEGALOVIRUS RETINITIS

被引:67
|
作者
AREVALO, JF
GONZALEZ, C
CAPPARELLI, EV
KIRSCH, LS
GARCIA, RP
QUICENO, JI
CONNOR, JD
GAMBERTOGLIO, J
BERGERONLYNN, G
FREEMAN, WR
机构
[1] UNIV CALIF SAN DIEGO,SHILEY EYE CTR 0946,DEPT OPHTHALMOL,LA JOLLA,CA 92093
[2] UNIV CALIF SAN DIEGO,DEPT PEDIAT,LA JOLLA,CA 92093
[3] UNIV CALIF SAN DIEGO,DEPT PHARM,LA JOLLA,CA 92093
[4] UNIV CALIF SAN FRANCISCO,DEPT PHARM,SAN FRANCISCO,CA 94143
来源
JOURNAL OF INFECTIOUS DISEASES | 1995年 / 172卷 / 04期
关键词
D O I
10.1093/infdis/172.4.951
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment, Undiluted vitreous samples were prospectively obtained from 60 eyes (52 patients) at the time of pars plana vitrectomy, Thirty-three plasma samples (from 27 patients in the initial group of 52) were obtained simultaneously during surgery on 33 eyes. High-pressure liquid chromatography showed the mean vitreous ganciclovir concentrations in patients on induction and maintenance therapy were, respectively, 4.74 +/- 1.49 mu M (n = 24) and 3.29 +/- 1.84 mu M (n = 30; P = .005). Simultaneous plasma ganciclovir concentrations were less than the vitreous concentrations in 78% of the patients. The mean intravitreous foscarnet concentrations in patients receiving induction dosages were 189 +/- 177 mu M (n = 5) versus 163 +/- 167 mu M (n = 4; P > .20) for those receiving maintenance therapy, The foscarnet vitreous plasma concentration ratio averaged 1.43, Current drugs and doses for CMV retinitis result in borderline or progressively subtherapeutic concentrations.
引用
收藏
页码:951 / 956
页数:6
相关论文
共 50 条
  • [1] FOSCARNET THERAPY FOR GANCICLOVIR-RESISTANT CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS
    JACOBSON, MA
    DREW, WL
    FEINBERG, J
    ODONNELL, JJ
    WHITMORE, PV
    MINER, RD
    PARENTI, D
    JOURNAL OF INFECTIOUS DISEASES, 1991, 163 (06): : 1348 - 1351
  • [2] COMBINATION THERAPY WITH FOSCARNET AND GANCICLOVIR FOR CLINICALLY RESISTANT CYTOMEGALOVIRUS RETINITIS IN PATIENTS WITH AIDS
    WEINBERG, DV
    MURPHY, RL
    HIRSCHTICK, RE
    SCURRY, J
    NAUGHTON, K
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 1993, 34 (04) : 1108 - 1108
  • [3] COMBINED DAILY THERAPY WITH INTRAVENOUS GANCICLOVIR AND FOSCARNET FOR PATIENTS WITH RECURRENT CYTOMEGALOVIRUS RETINITIS
    WEINBERG, DV
    MURPHY, R
    NAUGHTON, K
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 1994, 117 (06) : 776 - 782
  • [4] INTRAVITREAL GANCICLOVIR CONCENTRATION AFTER INTRAVENOUS ADMINISTRATION IN AIDS PATIENTS WITH CYTOMEGALOVIRUS RETINITIS - IMPLICATIONS FOR THERAPY
    KUPPERMANN, BD
    QUICENO, JI
    FLORESAGUILAR, M
    CONNOR, JD
    CAPPARELLI, EV
    SHERWOOD, CH
    FREEMAN, WR
    JOURNAL OF INFECTIOUS DISEASES, 1993, 168 (06): : 1506 - 1509
  • [5] FOSCARNET THERAPY OF CYTOMEGALOVIRUS RETINITIS IN AIDS
    FANNING, MM
    READ, SE
    BENSON, M
    VAS, S
    RACHLIS, A
    KOZOUSEK, V
    MORTIMER, C
    HARVEY, P
    SCHWARTZ, C
    CHEW, E
    BRUNTON, J
    MATLOW, A
    SALIT, I
    VELLEND, H
    WALMSLEY, S
    JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1990, 3 (05): : 472 - 479
  • [6] Combined intravenous ganciclovir and foscarnet for children with recurrent cytomegalovirus retinitis
    Walton, RC
    Whitcup, SM
    Mueller, BU
    Lewis, LL
    Pizzo, PA
    Nussenblatt, RB
    OPHTHALMOLOGY, 1995, 102 (12) : 1865 - 1870
  • [7] COMBINED THERAPY WITH GANCICLOVIR AND FOSCARNET FOR CYTOMEGALOVIRUS POLYRADICULOMYELITIS IN PATIENTS WITH AIDS
    KARMOCHKINE, M
    MOLINA, JM
    SCIEUX, C
    WELKER, Y
    MORINET, F
    DECAZES, JM
    LAGRANGE, P
    SCHNELL, L
    MODAI, J
    AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02): : 196 - 197
  • [8] Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS: The cytomegalovirus retreatment trial
    Lewis, RA
    Carr, LM
    Doyle, K
    Fainstein, V
    Gross, R
    Paskell, H
    Samo, TC
    Shigley, JW
    Jabs, DA
    Bartlett, J
    Becker, R
    Coleson, LC
    Dunn, JP
    Feinberg, J
    TayKearney, ML
    Leslie, J
    Miller, T
    Neisser, LG
    Semba, RD
    Barron, B
    Jarrott, C
    LeCount, C
    Peyman, G
    Swenie, D
    Heinemann, M
    OLeary, C
    Polsky, B
    Squires, K
    WiseCampbell, S
    Friedman, AH
    Cheung, TW
    Justin, N
    Sacks, H
    Severin, C
    Teich, S
    Wallach, F
    Friedberg, DN
    Addessi, A
    Dieterich, D
    Frost, K
    Hutt, R
    Pei, M
    Powers, T
    Scoppe, C
    Weinberg, DV
    Jampol, L
    Lyon, A
    Munana, A
    Murphy, R
    Naughton, K
    ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (01) : 23 - 33
  • [9] Cytomegalovirus retinitis in AIDS patients: A comparative study of intravenous and oral ganciclovir as maintenance therapy
    Danner, SA
    Matheron, S
    AIDS, 1996, 10 : S7 - S11
  • [10] Intravitreal and plasma cidofovir concentrations after intravitreal and intravenous administration in AIDS patients with cytomegalovirus retinitis
    Taskintuna, I
    Rahhal, FM
    Capparelli, EV
    Cundy, KC
    Freeman, WR
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1998, 14 (02) : 147 - 151